Pro Test Diagnostics – the next generation of anti-doping tests

Pro Test Diagnostics has developed a routine test to monitor and detect illegal use of one’s own stored blood to enhance performance in elite athletes. The ABT™-test can expose athletes who have used blood doping and the result is not affected by the athlete’s training intensity, the use of high-altitude training or the use of low oxygen tents.

Read more

Mucocort – treating recurrent aphthous ulcers

We are developing an oral patch, with a pending patented galenic formulation, providing immediate pain relief. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.

Read more

Quretech Bio – fighting bacterial virulence

Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance.

Read more

Metacurum Biotech AB – Novel antibody treatment for metastatic cancers

MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.

Read more

A novel treatment of acne vulgaris based on anti-biofilm protein

Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 700 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.

Read more

Morphobloc – new antifungal agents blocking virulence

Current drugs against mycoses are toxic. We aim to develop a new class of antifungal agents that disarm the invasive forms of fungal cells instead of merely eradicating them. This has two advantages: The new compounds are less aggressive for the host and resistance development is reduced.

Read more

Lipum – a novel treatment of chronic inflammations

Lipum develops a biological pharmaceutical for a novel mechanism of action in the treatment of chronic inflammations. The lead candidate drug (SOL-116) is a monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL. One indication is as an orphan drug for the more severe forms of Juvenile Idiopathic Arthritis (JIA), providing patients with an effective treatment alternative having less adverse effects than the drugs used today.

Read more

Hiloprobe AB – improved colorectal cancer diagnostics

Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.

Read more